Molsidomine

Molsidomine (CAS No.: 25717-80-0) is an important class of compound in the field of biomedical research, particularly occupying an important position in studies of cardiovascular dynamics and related diseases. As a nitric oxide (NO)-releasing prodrug, it undergoes metabolic activation in the liver to form the active metabolite Linsidomine, or SIN-1, thereby producing vasodilatory effects. This biochemical transformation process is mediated by hepatic esterases, and SIN-1 has a plasma half-life of 1 to 2 hours. Molsidomine can reduce myocardial oxygen consumption without altering coronary artery resistance, and has no obvious effect on heart rate or contractility, but it reduces stroke volume and cardiac output by decreasing preload and venous return. These pharmacodynamic properties make molsidomine a valuable tool in experimental models for exploring conditions such as angina pectoris and diabetic complications. Notably, the active concentration range of this compound spans from nanomolar to micromolar levels. Molsidomine is often used in various cellular and animal models, with its concentration adjusted according to the specific experimental design and research objectives. Because it can release nitric oxide and thereby promote vasodilation, it is a key research subject for exploring cardiovascular therapies, but its use is strictly limited to research contexts and does not involve clinical or therapeutic applications.